ClinicalTrials.gg
RecruitingNCT07864116CPP-LHUpdated Oct 7, 2026

Basal LH Threshold for the Diagnosis of Central Precocious Puberty

An observational study in Precocious Puberty, Central, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
4 Years to 11 Years
Sex
All
01

Study summary

This retrospective monocentric observational study aims to evaluate whether basal luteinizing hormone (LH) levels can reliably diagnose central precocious puberty and reduce the need for LHRH stimulation testing. Currently, all patients with suspected precocious puberty undergo LHRH testing regardless of basal LH levels.

The study will analyze pediatric patients evaluated between 2019 and 2024 to determine an optimal basal LH threshold with high specificity. Secondary analyses will assess diagnostic performance and explore clinical and biological factors influencing LH levels. The results may help reduce unnecessary testing and improve diagnostic strategies.

02

Conditions studied

  • Precocious Puberty, Central

Browse trials for

Keywords

  • Precocious puberty
  • Pediatric endocrinology
  • Diagnostic threshold
03

In context

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

This study's planned enrollment of 100 is below the median of 300 across 26 observational studies indexed under Puberty, Precocious.

Browse Puberty, Precocious studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children evaluated for suspected central precocious puberty in a pediatric day hospital setting, who underwent LHRH stimulation testing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4 to 11 years
  • Underwent LHRH stimulation testing for suspected precocious puberty between 01/01/2019 and 01/01/2024
  • No written opposition to reuse of medical data

Exclusion criteria

Exclusion Criteria:

  • Written opposition to data reuse
  • Age \<4 years or >11 years 11 months
  • LHRH test performed for indications other than suspected precocious puberty
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Basal LH threshold for diagnosis of central precocious puberty

    Determination of the basal LH level associated with a positive diagnosis of central precocious puberty (LH peak \>5 IU/L) and estimation of the number of LHRH stimulation tests that could have been avoided using this threshold.

    Time frame: At time of diagnostic evaluation (retrospective data from 2019-2024)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Nov 2, 2026
CompletionEst.
Jan 2, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07864116
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Mar 2, 2026
Primary completion
Nov 2, 2026 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Sylvie Rossignol, MD, PhD
Contact
sylvie.rossignol@chru-strasbourg.fr
33 3 88 12 77 34

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion